ライフサイエンスコーパス: cytogenetically

1 ere later confirmed to have inv(16)/t(16;16) cytogenetically.

2 large effects on bristle number were mapped cytogenetically.

3 Cytogenetically, a reduction in diploid chromosome numbe

4 xposures combined were possibly higher among cytogenetically abnormal 2.0 (95% confidence interval 0.

5 predictor of poor survival in patients with cytogenetically abnormal acute myeloid leukemia (CA-AML)

6 ssociated with favorable overall survival in cytogenetically abnormal AML (CA-AML) patients.

7 knowledge of exposure history, identified 75 cytogenetically abnormal and 139 normal (186 not studied

8 cals and radiation, the odds ratios for both cytogenetically abnormal and normal were marginally rais

9 Persistent cytogenetically abnormal cells at CR predict a significa

10 ure of these cells promoted the outgrowth of cytogenetically abnormal clones that, upon transplantati

11 matched controls were compared for 3 groups: cytogenetically abnormal, normal, and not known.

12 n that endothelial cells in solid tumors are cytogenetically abnormal.

13 Unexpectedly, tumor endothelial cells were cytogenetically abnormal.

14 e formation was particularly frequent in the cytogenetically adverse group, with subclone formation i

15 an independent adverse prognostic marker in cytogenetically adverse-risk AML.

16 Cytogenetically, all tumors are diploid or near diploid

17 This collection of cytogenetically anchored clones, representing nearly 7%

18 subset of chromosomal aberrations appearing cytogenetically and molecularly as simple terminal trunc

19 The dGCN2 gene was cytogenetically and physically mapped to the right arm o

20 are more frequent than previously recognized cytogenetically and that the deletions fall into four di

21 regions of chromosome 12 were characterized cytogenetically and were shown to have a normal compleme

22 particular type of recombination visualized cytogenetically as sister chromatid exchange (SCE), and

23 istinction that the t(X;17) translocation is cytogenetically balanced in these renal tumors.

24 In this study, we examined 237 cytogenetically characterized B-cell non-Hodgkin's lymph

25 Clear cell renal cell carcinoma (ccRCC) is cytogenetically characterized by chromosome 3p deletions

26 itially validated by analysis of a series of cytogenetically characterized cell lines, with the prese

27 marrow cells to trans-retinoic acid (RA) was cytogenetically characterized during RA treatment using

28 somal translocations, the mechanisms driving cytogenetically complex sarcomas are largely unknown.

29 Cytogenetically, complex > or = 5 predicted inferior dis

30 A cytogenetically cryptic (12;21) translocation is the mos

31 d-end sequencing allowed identification of a cytogenetically cryptic event: a 77-kilobase segment fro

32 of orang-utans from other Great Apes, that a cytogenetically cryptic pericentric inversion may have b

33 Here, we contrasted the genomic landscape of cytogenetically defined aphidicolin-induced CFSs (aCFSs)

34 refined legitimate fragile sites within the cytogenetically defined boundaries, and identified poten

35 In addition to the cytogenetically defined direct insertion of material fro

36 ltaneous gain of 1q21 and deletion of 17p in cytogenetically defined high-risk disease.

37 ells similar to those found in patients with cytogenetically defined high-risk disease.

38 We have placed 7,600 cytogenetically defined landmarks on the draft sequence

39 ubgroup analysis demonstrated that the three cytogenetically defined prognostic groups retained their

40 A cytogenetically defined region of the X chromosome, the

41 We demonstrate that the cytogenetically defined translocation t(X;1)(p11.2;p34)

42 was also found in 8 of 16 leiomyomas without cytogenetically detectable chromosome 6p21 aberrations b

43 rations of the protein product Patients with cytogenetically detectable deletions including JAG1 have

44 opies were found in individuals possessing a cytogenetically detectable elongation of the 15q region.

45 nts with loss of 5q, and 14 patients without cytogenetically detectable loss of 5q.

46 Although 8 of 9 MLL-AF4(+) infants had cytogenetically detectable t(4;11)(q21;q23), 15 of the 1

47 owever, between 30 and 50% of lymphomas with cytogenetically detectable translocations affecting band

48 ight cell lines, the deletions resulted from cytogenetically detectable whole chromosomal loss or lar

49 ic abnormalities considered as poor risk are cytogenetically detected chromosomal 13 or 13q deletion,

50 med a national cohort of 3425 women who were cytogenetically diagnosed with Turner syndrome in Great

51 Acute promyelocytic leukemia (APL), a cytogenetically distinct subtype of acute myeloid leukem

52 s paddlefish specific genome duplication are cytogenetically distinguishable.

53 ked proapoptotic activity against a panel of cytogenetically diverse primary human AML patient sample

54 in the PB plasma of all 45 patients who had cytogenetically documented chromosomal abnormalities (5q

55 ell lines also displayed significantly fewer cytogenetically evident alterations of chromosome struct

56 ine miR-10 family expression in 54 untreated cytogenetically heterogeneous AML patients was associate

57 miR-182 expression as a prognostic marker in cytogenetically high-risk acute myeloid leukemia patient

58 show few changes over time, whereas those of cytogenetically high-risk patients show significantly mo

59 Survival in cytogenetically high-risk patients with acute myeloid le

60 tly within Asparagus and sex chromosomes are cytogenetically identical with the Y, harboring a megaba

61 We determined the prognostic significance of cytogenetically identified breakpoints in 13q12-14 in ch

62 A t(1;19)(q23;p13) is detected cytogenetically in approximately 5% of childhood acute l

63 ed FISH probes that can discriminate between cytogenetically indistinguishable chromosome homologues.

64 1(MUT) levels in 1609 younger adult cases of cytogenetically intermediate-risk AML.

65 esolution by sequencing 141 breakpoints from cytogenetically interpreted translocations and inversion

66 gative acute promyelocytic leukemia that had cytogenetically invisible insertions.

67 Whole-genome sequencing can identify cytogenetically invisible oncogenes in a clinically rele

68 2 gene (HGMW-approved symbol, TAGLN), and we cytogenetically localized the gene to chromosome 11q23.2

69 u hybridization were used to genetically and cytogenetically map AgMuc1 to division 7A of the right a

70 With 69 new FISH assignments, a total of 253 cytogenetically mapped loci physically anchor the RH map

71 related gene, p73, was recently isolated and cytogenetically mapped to chromosome region 1p36.

72 seemingly pure terminal deletions visualized cytogenetically may be more complex, and BFB cycles may

73 ormation, we have defined the breakpoints of cytogenetically monocentric and dicentric Xq isochromoso

74 Only one of the eight cytogenetically monocentric i(Xq)s demonstrated a single

75 No FRAXE expansion events were found in 362 cytogenetically negative males studied, and one expansio

76 in the context of other molecular markers in cytogenetically normal (CN) -acute myeloid leukemia (AML

77 ations in older patients (aged >/=60 y) with cytogenetically normal (CN) acute myeloid leukemia (AML)

78 Cytogenetically normal (CN) acute myeloid leukemia (AML)

79 uated in 238 adults aged 18 to 59 years with cytogenetically normal (CN) de novo acute myeloid leukem

80 prognostic mutations in older (>/= 60 years) cytogenetically normal (CN) patients with AML (n = 134).

81 /NSD1 was found in 15% of FLT3/ITD and 7% of cytogenetically normal (CN)-AML.

82 ents with myelodysplastic syndrome (MDS) and cytogenetically normal acute myeloid leukemia (AML).

83 ) mutations associate with a poor outcome in cytogenetically normal acute myeloid leukemia (AML).

84 duplication (PTD) associates with high-risk cytogenetically normal acute myeloid leukemia (AML).

85 ene-/microRNA-expression profiles in primary cytogenetically normal acute myeloid leukemia (CN-AML) a

86 e prognostic markers in younger (< 60 years) cytogenetically normal acute myeloid leukemia (CN-AML) a

87 mitantly affect the outcome of patients with cytogenetically normal acute myeloid leukemia (CN-AML) b

88 Pediatric cytogenetically normal acute myeloid leukemia (CN-AML) i

89 PARC was among the most upregulated genes in cytogenetically normal acute myeloid leukemia (CN-AML) p

90 n levels are associated with poor outcome in cytogenetically normal acute myeloid leukemia (CN-AML) p

91 rognostic significance of MAP7 expression in cytogenetically normal acute myeloid leukemia (CN-AML) p

92 ce of FLT3 D835/I836 mutations (FLT3-TKD) in cytogenetically normal acute myeloid leukemia (CN-AML) r

93 Cytogenetically normal acute myeloid leukemia (CN-AML) w

94 s favorable prognosis in younger adults with cytogenetically normal acute myeloid leukemia (CN-AML),

95 arker in adults aged < 60 years with primary cytogenetically normal acute myeloid leukemia (CN-AML),

96 nsidered an independent prognostic factor in cytogenetically normal acute myeloid leukemia (CN-AML),

97 poietic stem cell transplantation (HSCT) for cytogenetically normal acute myeloid leukemia (CN-AML),

98 ion was associated with improved outcomes in cytogenetically normal acute myeloid leukemia (CN-AML).

99 g isocitrate dehydrogenases in adult de novo cytogenetically normal acute myeloid leukemia (CN-AML).

100 umor 1 gene (WT1) mutations in younger adult cytogenetically normal acute myeloid leukemia (CN-AML).

101 ed gene- and microRNA-expression profiles in cytogenetically normal acute myeloid leukemia (CN-AML).

102 most frequent submicroscopic alterations in cytogenetically normal acute myeloid leukemia and to con

103 Molecular study of cytogenetically normal acute myeloid leukemia is among t

104 n signature previously suggested to separate cytogenetically normal acute myeloid leukemia patients i

105 e same normal karyotype, adults with de-novo cytogenetically normal acute myeloid leukemia who consti

106 ated with favorable outcome in patients with cytogenetically normal acute myeloid leukemia.

107 ically relevant molecular genetic studies of cytogenetically normal acute myeloid leukemia.

108 nd found high LEF1 expression in a subset of cytogenetically normal AML (CN-AML) patients.

109 higher white blood cell counts (P < .0001), cytogenetically normal AML (CN-AML; P < .0001), NPM1 mut

110 rom adults under the age of 60 years who had cytogenetically normal AML and high-risk molecular featu

111 One feature of cytogenetically normal AML is alterations to the DNA met

112 signature in molecularly defined, high-risk, cytogenetically normal AML is associated with the clinic

113 a major impact on the clinical management of cytogenetically normal AML not only in prognostication b

114 Pretreatment blood samples from 84 cytogenetically normal AML patients aged less than 60 ye

115 and validation set (n = 105) of samples from cytogenetically normal AML patients from different popul

116 xpression signature that appears to separate cytogenetically normal AML patients into prognostic subg

117 t diagnosis correlated with poor survival in cytogenetically normal AML patients.

118 to identify transforming genes expressed in cytogenetically normal AML patients.

119 ion and cause perturbed enhancer activity in cytogenetically normal AML that contributes to a leukemi

120 ories, namely core-binding factor AML and/or cytogenetically normal AML, gene-expression and microRNA

121 al risk classifications in 214 patients with cytogenetically normal AML.

122 =60 y) and younger (age <60 y) patients with cytogenetically normal AML.

123 ting a frequency of 2.2% overall and 9.8% in cytogenetically normal AML.

124 profiling strategy for outcome prediction in cytogenetically normal AML.

125 Cells from 1 histologically and cytogenetically normal bronchial epithelial primary cult

126 Herein we show that in cytogenetically normal cases of AML and in cases with +1

127 nisms of leukemogenesis, we asked whether in cytogenetically normal cases one or both chromosomes car

128 act as a disease gene marker for these often cytogenetically normal disorders.

129 ocus for recurrent spontaneous abortion in a cytogenetically normal family.

130 lite DNA sequence variants, that distinguish cytogenetically normal homologous chromosomes by FISH.

131 er cell line and in telomerase immortalized, cytogenetically normal human breast epithelial cells usi

132 e 5 or 7 abnormalities) who achieved CR were cytogenetically normal in CR.

133 e observed when using a second cohort of 183 cytogenetically normal older (age >/= 60 years) AML pati

134 otypes had significantly worse outcomes than cytogenetically normal patients.

135 togenetic status; it was present in 13 of 80 cytogenetically normal samples (16%).

136 ly one of 124 patients reported initially as cytogenetically normal was ultimately RT-PCR-positive.

137 nge, 19 to 65 years), 29 patients (39%) were cytogenetically normal, and 11 (15%) had FLT-3 internal

138 f coverage (approximately 98%) of a primary, cytogenetically normal, de novo genome for AML with mini

139 a (AML), a large percentage of AML cases are cytogenetically normal.

140 The doubling time for patients relapsing cytogenetically or into chronic phase (median, 24.7 days

141 Thus, using the anti-inv(16) Ab, all cytogenetically positive and RT-PCR-positive AML cases w

142 detected in two related females known to be cytogenetically positive for a fragile site in Xq27.3-28

143 specifically detected all 23 cases that were cytogenetically positive for inv(16) or t(16;16), includ

144 duals have 6-35 copies of the repeat whereas cytogenetically positive, developmentally delayed males

145 have determined the extent of allele loss in cytogenetically prescreened MDS and AML patients for mic

146 sion event involving normal, nontransformed, cytogenetically stable epithelial cells can initiate chr

147 iploid, had normal centrosomes, and remained cytogenetically stable in culture even up to 20 passages

148 ous alpha satellite DNA, are mitotically and cytogenetically stable in the absence of selection for u

149 ed in a blinded fashion to a series of eight cytogenetically t(2;5)-positive clinical specimens and s

150 wo groups, proteins are virtually identical, cytogenetically there are few rearrangements that distin

151 cence in situ hybridization, we map the gene cytogenetically to band 12q21.

152 jority of patients with 18q- syndrome appear cytogenetically to have a terminal deletion of the long

153 e-insert jumping libraries to delineate both cytogenetically visible and cryptic SVs in a single test

154 Subsequently, an interstitial, cytogenetically visible deletion in Xq25 was identified

155 Although sex chromosomes are not cytogenetically visible in this species, several lines o

156 Cytogenetically visible interstitial deletions involving

157 ed hemizygous deletions, consistent with the cytogenetically visible loss; no homozygous deletions we

158 Many cytogenetically visible, apparent terminal deletions are

159 f 12 with AML; six of these seven also had a cytogenetically-visible del(5q) or -5.

160 d variation in gene-expression patterns in a cytogenetically well-defined series of cell lines derive

161 to have its signature translocation defined cytogenetically, which led to the identification of its

162 on proximity to a gene that has been mapped cytogenetically, within band 3q13.31.